WO2003057155A2 - Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor - Google Patents
Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor Download PDFInfo
- Publication number
- WO2003057155A2 WO2003057155A2 PCT/US2002/041607 US0241607W WO03057155A2 WO 2003057155 A2 WO2003057155 A2 WO 2003057155A2 US 0241607 W US0241607 W US 0241607W WO 03057155 A2 WO03057155 A2 WO 03057155A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- met
- radionuclide
- therapeutic
- antibody
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 221
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 title claims description 10
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 title claims description 10
- 238000003384 imaging method Methods 0.000 title abstract description 57
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 172
- 238000000034 method Methods 0.000 claims abstract description 117
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 33
- 238000003745 diagnosis Methods 0.000 claims abstract description 17
- 238000012544 monitoring process Methods 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 153
- 230000001225 therapeutic effect Effects 0.000 claims description 92
- 230000027455 binding Effects 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 68
- 210000001519 tissue Anatomy 0.000 claims description 52
- 238000001727 in vivo Methods 0.000 claims description 47
- 108091007433 antigens Proteins 0.000 claims description 38
- 102000036639 antigens Human genes 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 35
- 238000002347 injection Methods 0.000 claims description 27
- 239000007924 injection Substances 0.000 claims description 27
- 210000004881 tumor cell Anatomy 0.000 claims description 25
- 239000000523 sample Substances 0.000 claims description 24
- 210000000056 organ Anatomy 0.000 claims description 23
- -1 ιπIn Chemical compound 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 238000001802 infusion Methods 0.000 claims description 13
- 230000033115 angiogenesis Effects 0.000 claims description 12
- 230000035755 proliferation Effects 0.000 claims description 12
- 230000009545 invasion Effects 0.000 claims description 11
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 239000010949 copper Substances 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 230000005012 migration Effects 0.000 claims description 10
- 238000013508 migration Methods 0.000 claims description 10
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 9
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 9
- 239000010931 gold Substances 0.000 claims description 8
- 229960003330 pentetic acid Drugs 0.000 claims description 8
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 7
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 claims description 5
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 claims description 5
- 108010053210 Phycocyanin Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 claims description 4
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052693 Europium Inorganic materials 0.000 claims description 3
- 108010004729 Phycoerythrin Proteins 0.000 claims description 3
- 108010004469 allophycocyanin Proteins 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 abstract description 37
- 230000001394 metastastic effect Effects 0.000 abstract description 14
- 206010061289 metastatic neoplasm Diseases 0.000 abstract description 14
- 238000001514 detection method Methods 0.000 abstract description 11
- 239000003446 ligand Substances 0.000 abstract description 9
- 239000000556 agonist Substances 0.000 abstract description 4
- 238000004393 prognosis Methods 0.000 abstract description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 74
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 67
- 230000000694 effects Effects 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 30
- 101001039684 Homo sapiens mRNA cap guanine-N7 methyltransferase Proteins 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 28
- 102100040949 mRNA cap guanine-N7 methyltransferase Human genes 0.000 description 28
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 239000003814 drug Substances 0.000 description 22
- 241001529936 Murinae Species 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 230000003305 autocrine Effects 0.000 description 12
- 238000010166 immunofluorescence Methods 0.000 description 12
- 238000012633 nuclear imaging Methods 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000002372 labelling Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000003472 neutralizing effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000013592 cell lysate Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 238000002595 magnetic resonance imaging Methods 0.000 description 8
- 230000037081 physical activity Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 241000282465 Canis Species 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 201000001514 prostate carcinoma Diseases 0.000 description 7
- 230000007306 turnover Effects 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 238000000163 radioactive labelling Methods 0.000 description 6
- 238000011363 radioimmunotherapy Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- 102000027430 HGF receptors Human genes 0.000 description 5
- 108091008603 HGF receptors Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 108010039491 Ricin Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000012217 radiopharmaceutical Substances 0.000 description 5
- 229940121896 radiopharmaceutical Drugs 0.000 description 5
- 230000002799 radiopharmaceutical effect Effects 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001685 thyroid gland Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 208000036815 beta tubulin Diseases 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000003269 fluorescent indicator Substances 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 102000057308 human HGF Human genes 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000013517 stratification Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000009400 cancer invasion Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 210000005170 neoplastic cell Anatomy 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 210000000064 prostate epithelial cell Anatomy 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000010244 region-of-interest analysis Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229960005267 tositumomab Drugs 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 108010066676 Abrin Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960003272 asparaginase Drugs 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940074045 glyceryl distearate Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- GBECUEIQVRDUKB-UHFFFAOYSA-M thallium monochloride Chemical compound [Tl]Cl GBECUEIQVRDUKB-UHFFFAOYSA-M 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- ONJXCGCIKIYAPL-MLRSDOHDSA-K 2-[2-[[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-16-benzyl-4-[[(2r,3r)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phe Chemical compound [111In+3].C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)NC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O)C1=CC=CC=C1 ONJXCGCIKIYAPL-MLRSDOHDSA-K 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BNBQQYFXBLBYJK-UHFFFAOYSA-N 2-pyridin-2-yl-1,3-oxazole Chemical class C1=COC(C=2N=CC=CC=2)=N1 BNBQQYFXBLBYJK-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
- YEEGWNXDUZONAA-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-gallabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Ga+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YEEGWNXDUZONAA-UHFFFAOYSA-K 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 101100400999 Caenorhabditis elegans mel-28 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000037162 Ductal Breast Carcinoma Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 150000008064 anhydrides Chemical group 0.000 description 1
- GQKVCZAPFYNZHX-UHFFFAOYSA-N anthracene-2,3-dicarboxylic acid Chemical compound C1=CC=C2C=C(C=C(C(C(=O)O)=C3)C(O)=O)C3=CC2=C1 GQKVCZAPFYNZHX-UHFFFAOYSA-N 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124536 anticoccidial agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- QCUOBSQYDGUHHT-UHFFFAOYSA-L cadmium sulfate Chemical compound [Cd+2].[O-]S([O-])(=O)=O QCUOBSQYDGUHHT-UHFFFAOYSA-L 0.000 description 1
- 229910000331 cadmium sulfate Inorganic materials 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003224 coccidiostatic agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical group [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 1
- 229960003460 gadopentetic acid Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- YCXSYMVGMXQYNT-UHFFFAOYSA-N methyl 3-[(4-azidophenyl)disulfanyl]propanimidate Chemical compound COC(=N)CCSSC1=CC=C(N=[N+]=[N-])C=C1 YCXSYMVGMXQYNT-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012514 monoclonal antibody product Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- KHARCSTZAGNHOT-UHFFFAOYSA-L naphthalene-2,3-dicarboxylate Chemical compound C1=CC=C2C=C(C([O-])=O)C(C(=O)[O-])=CC2=C1 KHARCSTZAGNHOT-UHFFFAOYSA-L 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940127059 octreoscan Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108700023050 pentetreotide Proteins 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229950001030 piritrexim Drugs 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108700028325 pokeweed antiviral Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000009258 post-therapy Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003220 pyrenes Chemical class 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004054 semiconductor nanocrystal Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- FVAUCKIRQBBSSJ-LAIFMVDKSA-M sodium;iodine-131(1-) Chemical compound [Na+].[131I-] FVAUCKIRQBBSSJ-LAIFMVDKSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000009662 stress testing Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940081330 tena Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention in the field of medicine, immunology and cancer diagnosis and therapy, is directed to monoclonal antibody (mAb) compositions that are useful for imaging and treating tumors that express the Met oncogene product and bind hepatocyte growth factor/scatter factor.
- mAb monoclonal antibody
- a person with a low MRS score would be considered to have a tumor at low risk of metastatic or invasive behavior, and could be monitored and treated conservatively; one with an intermediate MRS score could be treated conservatively but monitored frequently; and one at high risk by MRS would have an objective basis for agreeing to and enduring a correspondingly more aggressive therapy and intensive monitoring protocol.
- Every dividing cell has the potential to become neoplastic, and every neoplasm has the potential to become simply malignant, i.e., able to invade and metastasize.
- molecular oncologists have sought molecules that are important in, characteristic of, and potentially diagnostic for, carcinogenesis and cancer progression for over twenty years.
- Met the protein product of the c-zwet-protooncogene, was discovered and studied in the laboratory of George Vande Woude at the National Cancer Institute beginning in 1984 (Cooper CS et al, 1984, Nature 311:29-33; Dean M et al, 1985, Nature 318:385-388; Iyer A et al, 1990, Cell Growth Differ 1 : 87-95)
- Met is a receptor protein tyrosine kinase of the same family as epidermal growth factor (EGF) receptors. This transmembrane protein acts as the cell surface membrane receptor in which the extracellular domain (ECD) binds hepatocyte growth factor/scatter factor (HGF/SF, also abbreviated HGF herein).
- Met dimerizes after binding ligand to form the active kinase.
- the intracellular tyrosine kinase domain activates a complex cascade of biochemical reactions.
- Met is a keystone molecule, acting on the molecular signaling pathways responsible for cellular differentiation, motility, proliferation, organogenesis, angiogenesis, and apoptosis (Haddad R et al, 2001, Anticancer Res 21:4243- 4252).
- HGF neoplastic cells the aberrant expression of Met and HGF leads to emergence of an invasive/metastatic phenotype.
- Met-HGF expression in general correlate inversely with clinical outcome. This correlation has been examined in greatest detail for human breast and prostate carcinomas. Met overexpression in breast tumors is associated with breast cancer progression (Niemann C et al, 1998, J Cell Biol 143:533-545; Tsarfaty I et al, 1999, Anal Quant Cytol Histol 21 :397-408; Firon M et al, 2000, Oncogene 19:2386-2397) and high HGF expression also correlates with poor survival in ductal breast carcinomas (Yamashita JI et al, 1994, Cancer Res 54:1630-1633; Ghoussoub RAD et al, Cancer 82:1513-1520).
- Tsarfaty et al supra quantified Met expression in uninvolved (N) relative to tumor (T) tissue in the same primary breast carcinoma sections.
- Met provides a strong selective mechanism for metastatic growth in prostate cancer (Humphrey PA et al, 1995, Am J Pathol 147:386-396; Pisters LL et al, 1995, J Urol 154:293- 298; Watanabe M et al, 1999, Cancer Lett 141:173-178; Knudsen BS et al, 2002, Urology, 60:1113-1117)).
- Met can be considered the "poster child" of very malignant cancers in that (1) very malignant cancers express Met independently of the tissue of origin, and (2) Met is a process-specific rather than tissue-specific marker for cancer, an indicator of tumor destiny rather than of tumor origin.
- the present inventors set out to utilize molecular imaging to exploit Met in order to determine the status of Met expression in particular solid tumors in vivo, and armed with that information, to design Met-directed therapies that will alter tumor destiny toward a more favorable clinical outcome.
- the present disclosure describes the development of molecular imaging tools and approaches to clarify the behavior of Met at the cellular level, and apply these approaches to in vivo animal models of human cancer and to naturally occurring human cancers.
- the mAbs were selected following immunization of mice with whole live GTL-16 cells (human gastric carcinoma cell line) overexpressing Met. Hybrid supematants were screened for binding to GTL-16 cells. Four mAbs referred to as DL-21, DN-30, DN-31 and DO-24, were selected.
- the mAb DO-24 was reported to be an IgG2a isotype antibody.
- Radioimmunoscintigraphy is an important and attractive modality for experimental and clinical molecular imaging of cancer.
- Established methods for radiolabeling mAbs in suitable quantity and of appropriate quantity for scintigraphy are available, feasible, relatively inexpensive, and adaptable to virtually any mAb regardless of its epitopic specificity.
- scintigraphy as a molecular imaging modality (not limited to imaging with antibodies) is that the acquired images are inherently quantitative.
- the physics of gamma radiation and the mathematical analysis of nuclear images, including corrections for photon attenuation and other artifacts, are well understood, hi animal models as well as in human studies we can noninvasively and accurately measure net accumulation and some kinetic parameters of radiopharmaceutical interactions with target lesions, and the concurrent collection of even a small set of biological samples (e.g., blood and excreta) for direct counting combined with quantitative analysis of diagnostic images enables us to make useful dosimetry estimates for therapeutic purposes.
- biological samples e.g., blood and excreta
- radiopharmaceuticals are available for imaging neoplasms. They range from classical agents such as sodium iodide (Na- 131 I), thallium chloride ( 201 T1C1), and gallium citrate ( Ga-citrate) to highly selective positron-emitting reporter gene detection systems (Vallabhajosula S (2001), In: Nuclear Oncology. I Khalkhali et al, eds. Lippincott Williams & Wilkins, Philadelphia, PA. pp. 31-62; Iyer M et al. (2001) J Nucl Med 42, 96-105).
- Radiolabeled molecules that bind to specific cell surface components provide one successful approach to tumor imaging and therapy. Examples are OctreoScan® for imaging and potentially treating neuroendocrine neoplasms, CEAScan® and OncoScint® for imaging colorectal and ovarian cancers, and Bexxar® and Zevalin® for detecting and treating certain lymphomas. As a novel variation of that strategy, the present inventors have begun to develop radiopharmaceuticals (as well as related diagnostic and therapeutic agents) that are designed to distinguish neoplasms according to their genotype and invasive/metastatic potential rather than by tissue of origin, based on targeting of the Met oncogene product.
- tissue-specific mAbs as diagnostic and therapeutic agents, the present inventors have developed antibody-based agents, exemplified in the form of radiopharmaceuticals, that distinguish neoplasms according to their genotype and invasive and/or metastatic potential rather than by their tissue of origin. Such antibodies are specific for extracellular epitopes of the Met oncogene protem product.
- the present inventors raised and characterized mAbs against the ECD of human Met ("hMet” or "huMet”); they also produced antibodies specific for human HGF (“hHGF” or "huHGF”).
- anti-hMet and anti-HGF antibodies or combinations thereof can be used to image in vivo human tumors expressing or secreting the protein for which these mAbs are specific (in nude mice).
- Several novel anti-Met mAbs were produced against hMet and characterized.
- the hybridoma cell lines producing these mAbs were deposited in the American Type Culture Collection under Accession Number PTA-4349 and PTA-4477.
- These antibodies (Met3 and Met5) bind to hMet in immunoassay such as ELISA or indirect IF against tumor cells known to express high levels of hMet, or by antibody inhibition of biological or biochemical activity, such as in a scatter assay or urokinase-stimulation assay.
- Radioiodinated anti-hMet mAbs derived from one hybridoma designated 2F6 ( Met3), either radiolabeled alone or in combination with a neutralizing mixture of anti-hHGF mAbs, rapidly and effectively detected tumors autocrine for hMet and hHGF as demonstrated by gamma camera scintigraphy of mice bearing such tumors. At least two anti-hMet mAbs were shown to be agonists when binding Met. At least one anti-hMet mAb was a potent antagonist when binding Met.
- the present invention is thus directed to the following new mAbs
- aha mAb, or antigen-binding fragment or derivative thereof that has all the identifying biological characteristics of the above mAbs, fragments or derivatives.
- One embodiment includes a humanized mAb (or an antigen binding fragment or derivative )specific for Met, wherein the heavy chain and/or light chain V region of the anti-Met mAb, or an antigen binding site of the V region, has all the identifying biological or structural characteristics of the corresponding regions or sites of the above new mAbs, and substantially all the remainder of the humanized mAb is of human origin.
- a human mAb specific for Met that binds to the same epitope as the epitope to which the above mAb (Met3 or Met5 binds, or an antigen binding fragment or derivative of the human antibody.
- compositions comprising the above mAb, fragment or derivative.
- This composition may further comprise one or more additional antibodies specific for a Met epitope, or may comprise an antigen-binding fragment or derivative of the additional one or more antibodies.
- the above composition may further comprise one or more antibodies, fragments or derivatives specific for HGF.
- the anti-HGF is selected from the group consisting of: (a) a mAb produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-3414; (b) a mAb produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-3416;
- a preferred composition is diagnostically useful in that at least one of the antibodies in the composition carries (is bound to, conjugated to or labeled with) a suitable diagnostic or detectable label, preferably one detectable in vivo.
- detectable labels include radionuchdes, PET-imageable agents, MRI-imageable agents, fluorescers, fmorogens, a chromophore, a chromogen, a phosphorescer, a chemiluminescer or a bioluminescer.
- Such a label permits detection or quantitation of the Met or HGF level in a tissue sample and can be used, therefore, as a diagnostic and a prognostic tool in a disease where expression or enhanced expression of Met (or its binding of HGF) plays a pathological or serves as a diagnostic marker and/or therapeutic target, particularly, cancer.
- a preferred radionuclide is selected from the group consisting of 3 H, 14 C, 35 S, 99 Tc, 123 1, 125 1, 131 I, m In, 97 Ru, 67 Ga, 68 Ga, 72 As, 89 Zr and 201 T1.
- a most preferred label is 125 I.
- Preferred in vivo detection is by radioimmunoscintigraphy.
- the fluorescer or fluorogen is preferably fluorescein, rhodamine, dansyl, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine, a fluorescein derivative, Oregon Green, Rhodamine Green, Rhodol Green or Texas Red.
- a diagnostic label is bound to the antibody protein through one or more diethylenetriaminepentaacetic acid (DTP A) residues that are coupled to the protein.
- the label is bound through one DTPA residue.
- DTP A diethylenetriaminepentaacetic acid
- One preferred diagnostic method is MRI using these labeled proteins.
- a number of metals (not radioisotopes) useful for MRI include gadolinium, manganese, copper, iron, gold and europium. Gadolinium is most preferred.
- the amount of labeled antibody needed for detectability in diagnostic use will vary depending on considerations such as age, condition, sex, and extent of disease in the patient, contraindications, if any, and other variables, and is to be adjusted by the individual physician or diagnostician. Dosage can vary from 0.01 mg/kg to 100 mg/kg of each single antibody or combination of antibodies.
- the present invention provides a method for detecting the presence of Met (i) on the surface of a cell, (ii) in a tissue, (iii) in an organ or (iv) in a biological sample, which cell, tissue, organ or sample is suspected of expressing Met, comprising the steps of:
- the contacting and the detecting may be in vitro; the contacting may be is in vivo and the detecting in vitro, or, preferably, the contacting and the detecting are in vivo.
- the method may be carried out for purposes of diagnosis, prognosis, and/or monitoring (e.g., post- therapy).
- In vivo detection is preferably of a radionuclide as above, preferably by radioimmunoscintigraphy.
- the method may also utilize a detectable label that is an MRI- imageable agent and use MRI to detect the binding and the localization of the Met-expressing tumor.
- a method of determining the progression of Met-expressing cancer comprises: a) contacting a tissue sample from a patient having cancer with the antibody composition as above; b) detecting the binding of the antibodies to Met; c) measuring the amount of Met (or HGF) in the sample; and d) correlating the antibody binding with a clinically defined stage of cancer development.
- a method for detecting the presence of Met-expressing cancer in a patient comprises : a) contacting a tissue sample from the subject with the above antibody composition; b) detecting the binding of the antibodies with Met (and, optionally, with HGF) in the sample, whereby increased binding of antigen to the antibodies relative to the binding of antigen from a control tissue sample to the antibodies indicates an increased amount of Met in the sample, whereby the increased amount of Met indicates the presence of cancerous tissue in the sample.
- a therapeutic composition useful for treating a Met-expressing tumor in which at least one of the antibodies (or fragment or derivative) carries a suitable therapeutic "label” also referred to herein as a "therapeutic moiety.”
- a therapeutic moiety is an atom, a molecule, a compound or any chemical component added to the protem that renders it active in treating a disease or condition associated with expression of Met and HGF.
- the therapeutically active moiety may be bound directly or indirectly to the protein.
- the therapeutically labeled polypeptide (antibody, fragment, derivative) protein is administered as pharmaceutical composition which comprises a pharmaceutically acceptable carrier or excipient, and is preferably in a form suitable for injection.
- Preferred therapeutic moieties are radionuchdes, for example 47 Sc, 67 Cu, 90 Y, 10 Pd, 25 L
- This invention includes an article of manufacture and a related kit.
- the kit may comprise
- the antibody, fragment or derivative is effective for diagnosing, prognosing, monitoring or treating the condition and the label on the labeled container indicates that the antibody can be used for the diagnosing, prognosing, monitoring or treating, as the case may be. Also provided is a method for inhibiting (i) the proliferation, migration, or invasion of,
- Met-expressing tumor cells or (ii) angiogenesis induced by Met-expressing tumor cells, comprising contacting the cells with an effective amount of the above therapeutic composition.
- the contacting is in vivo.
- the therapeutic composition is preferably one in which at least one of the antibodies, fragments or derivatives is bound to, conjugated to, or labeled with a therapeutic moiety.
- This invention is directed to a method for treating a subject having a cancerous disease or condition associated with (i) undesired proliferation, migration or invasion of Met-expressing cells or (ii) undesired angiogenesis induced by Met-expressing cells, comprising administering to the subject an effective amount of the above therapeutic composition, preferably one in which at least one of the antibodies, fragments or derivatives is bound to, conjugated to, or labeled with a therapeutic moiety.
- Figure 1A-1D shows an immunofluorescence (IF) analysis of tumors using anti-hMet mAbs.
- S-114 cells fixed in acetone/methanol were labeled with either (A) anti-Met mAb 2F6 followed by FITC-conjugated anti-mouse IgG (green, Fig. 1 A) or (B) a polyclonal anti-Met rabbit antibody C-28 (Santa Cruz) followed by rhodamine-conjugated anti-rabbit IgG (red, Figure IB).
- Fig. IC confirms colocalization (yellow) of the antigens recognized by the mAb and the polyclonal antibody.
- Fig. ID shows a Nomarski-Differential hiterference Contrast image of the cells from Fig. 1-lC.
- FIG. 2 shows a series of total body images of tumor-bearing mice injected with an I- labeled mAb mixture that includes antibodies specific for hHGF and those specific for hMet.
- Each row of images contains serial total body scintigrams for a single tumor-bearing mouse injected with this 125 I-mAb mixture.
- the tumor in each mouse is indicated to the left of its row.
- Below each column is shown the time after mAb injection at which each image was acquired. Images were obtained in posterior projection for the upper three rows, and in anterior projection for the mouse bearing DA3.
- the large arrows mark the transverse positions of respective tumors. Asterisks indicate the transverse positions of thyroids.
- the small arrow over the 1-day postinjection image for the mouse bearing DA3 indicates urinary bladder activity.
- Extracorporeal radioactivity in the upper right corner of each scintigram for the mouse bearing M-l 14 represents a positional marker
- Figure 3 A and 3B show an ROI comparison of tumors expressing hHGF and hMet vs. tumors expressing mHGF and/or mMet.
- mice bearing tumors that grow in autocrine fashion due to hMet and hHGF (3 mice bear S-l 14, 1 mouse bears SK-LMS-1) and three mice bearing tumors expressing mHGF and/or m (2 mice bear DA3, 1 mouse bears M-l 14) were injected with an 125 I-labeled mAb mixture specific for hMet and hHGF/SF.
- T Tumor radioactivity
- WB whole body radioactivity
- FIG 4 is a schematic representation of mechanisms by which the radiolabeled mAbs bind to tumor cells.
- Radiolabeled anti-Met mAb (*anti-Met) is depicted as binding directly to Met expressed on the tumor cell surface.
- Radiolabeled anti-HGF mAb (*anti-HGF/SF) could either bind to free HGF concentrated in the extracellular milieu, thereby surrounding tumor cells with radiolabeled soluble complexes, or could form a ternary complex of mAb:HGF:Met at the cell surface.
- FIG. 5 A, 5B and -5C/1-5C/3 characterize the reactivity of anti-Met mAb "Met3.”
- Fig. 5 A shows ex vivo immunohistochemical staining with Met3.
- a formalin-fixed, paraffin- embedded sample of human prostate tissue was examined immunohistochemically with Met3.
- Met expression is shown by dark brown staining in normal prostate epithelium. The staining is most prominent in the basal cell layer (arrow).
- Fig. 5B shows that Met3 binds Met in cultured normal human prostate epithelial cells.
- a primary culture of normal human prostate epithelial cells was examined by IF with Met3 (green; left half of Fig. 5B) and with C-28 polyclonal antibody (red; right half of Fig. 5B).
- Fig. 5C/1-5C/3 shows that Met3 binds to the surfaces of PC-3 and DU145 prostate cancer cells: FACS analysis with Met3 (thicker green curve shifted to the right) shows surface staining in the Met-expressing PC-3 and DU145 cell lines, but not in the LNCaP cell line (which exhibits very low levels of Met expression).
- Figure 6 shows Met expression by selected human cancer cell lines.
- the indicated cultured cell lines were grown in DMEM containing 10% fetal bovine serum (FBS) to near- confluency. Normalized aliquots of cell lysates were subjected to SDS-polyacrylamide gel electrophoresis, electrotransfer, and immunodecoration with C-28 anti-Met polyclonal antibody (upper panel) followed by H-235 anti- ⁇ -tubulin polyclonal antibody (lower panel). Immune complexes were identified by enhanced chemiluminescence. Relevant regions of the resulting luminograms are shown.
- FBS fetal bovine serum
- Figure 7 shows scintigrams of tumor xenografts.
- the indicated cell lines were injected subcutaneously in the posterior aspect of the right thigh or in the adjacent portion of the right flank (for melanomas) of female athymic nude mice to induce xenografts.
- Host animals underwent radioimmunoscintigraphy with 125 I-Met3 (50-100 ⁇ Ci given intravenously when their tumors reached > 0.5 cm in greatest dimension.
- a composite of serial posterior whole body scintigrams for individual animals bearing tumors as indicated on the left is shown, from 1-2 hours to 5-6 days postinjection. Arrows indicate the locations of tumor xenografts.
- the midline focus of activity evident near the xenograft at some time points in some animals represents radioiodide in the urinary bladder.
- the craniadmost focus of activity in each image represents liberated radioiodide uptake by the thyroid.
- Figures 8A-8B show a region-of-interest (ROI) analysis of scintigrams. Serial scintigrams for each host animal were evaluated by quantitative ROI analysis.
- Fig. 8A depicts the estimated percent of injected activity associated with the tumor xenografts as a function of time postinjection.
- ROI region-of-interest
- Figures 9 A and 9B shows the presence of activated Met in dog cells.
- Cells of the canine kidney cell line MDCK were cultured and exposed to HGF at the indicated concentrations.
- Cell lysates were prepared and immunoprecipitated with Met5 followed by electrophoresis, electrotransfer, and immunodecoration with anti-PY 4G10 (anti-phosphotyrosine antibody)to detect activated (phosphorylated) Met.
- SKLMS-1 cells were similarly processed as a known positive control (Met-positive, HGF-responsive).
- Figure 10 similar to Figs. 9A/9B, shows activated Met in dog cells. Cultured MDCK cells (a canine kidney line) were exposed to HGF at the indicated concentrations.
- FIGS. 11 A-l IC show a FACS analysis of Met3 binding to PC-3 human prostate carcinoma cells.
- a shift of fluorescent indicator (dye-conjugated anti-mouse Ab) in the presence of Met3 to larger particle size reflects association with cells.
- Figures 12A-12C show a FACS analysis of Met5 binding to MDCK canine kidney cells. Met5 induced a shift of fluorescent indicator (dye-conjugated anti-mouse antibody) to larger particle size reflecting association with cells.
- fluorescent indicator die-conjugated anti-mouse antibody
- Figures 13A-13D show results of nuclear imaging of human tumor xenografts with 125 I- Met5.
- Xenografts of the human nasopharyngeal carcinoma cell line CNE-2 and the renal cell carcinoma cell line, 769-P were grown subcutaneously in the right thighs of nude mice (3 mice/group). Each mouse was injected i.v. with 125 I-Met5, and serial gamma camera images were obtained (1 hour to 5 days postinjection). Arrows appended to the image of one mouse in each group indicate the subcutaneous (thigh) tumor locations.
- HGF Inappropriate expression of Met and/or of its ligand, HGF correlates with poor prognosis -> in a variety of human solid tumors.
- the present inventors have developed animal models for nuclear imaging of Met and HGF expression in tumors in vivo using several novel anti-Met mAbs and/or a combination of an anti-Met mAb with one or more anti-HGF mAbs.
- the present inventors disclosed that Met-expressing tumor xenografts in nude mice can be visualized as early as one hour following injection of radiolabeled anti-Met alone or in combination with anti- 0 HGF mAbs, with peak image contrast (activity in tumor vs. whole body) occurring at about three days postinjection in one case.
- Met-expressing tumor xenografts exhibit a range of initial uptake of the radiolabeled mAb from about 5% to 20% of the estimated injected activity.
- Tumor- associated radioactivity constituted from about 10 to about 40% of total body activity at peak image contrast.
- the turnover of radiolabeled mAbs appeared to be substantially more rapid in -> tumor xenografts exhibiting higher initial uptake values.
- Antibodies are polypeptides known also as immunoglobulin (Ig) molecules, which exhibit binding specificity to a specific antigen or epitope.
- antibody is broad, extending beyond the conventional intact 4-chain Ig molecule (characteristic of IgG, IgA and IgE antibodies).
- An antibody may occur in the form of polyclonal antibodies (e.g., fractionated or unfractionated immune serum) or a mAb (see below).
- Ig molecules with more than one antigen-specificity e.g., a bispecific antibody formed by joining antigen-binding regions or chains from two different antibodies.
- Antibodies are typically polypeptides which exhibit binding specificity to a specific antigen.
- a native Ig molecule is typically a heterotetrameric glycoprotein, composed of two identical light (L) chains and two identical heavy (H) chains, with each L chain linked to a H chain by one interchain disulfide bond. Additional disulfide linkages bridge the two H chains.
- Each H and L chain has regularly spaced intrachain disulfide bonds.
- the N-terminus of each H chain and each L chain includes a variable (V) domain or region (V H and V L ).
- V H and V L TO the C-terminal side of the V H domains are a number of constant (C) domains (C H ); L chains have only a single C domain at its c-terminus (termed C L ). Particular amino acid residues form an interface between the VH and VL domains.
- Vertebrate L chains are assigned to one of two distinct types, also called isotypes, K and ⁇ , based on the amino acid sequences of their C domains.
- Igs are members of different classes: IgG, IgM, IgA, IgE and IgD, identified by their H chains referred to respectively as ⁇ , ⁇ , ⁇ , ⁇ and ⁇ .
- IgG isotypes IgG 1 ⁇ IgG 2 , IgG 3 , and IgG (comprising the H chains known as ⁇ l, ⁇ 2, ⁇ 3 and ⁇ 4, respectively), or the IgA isotypes IgA 1 and IgA 2 (comprising the H chains ⁇ l and ⁇ 2, respectively).
- variable refers to amino acid sequences which differ among different antibodies and which are responsible for the antibody's antigen-specificity. Sequence the variability is evenly distributed throughout the V region but is typically greater in three particular regions, termed complementarity determining regions (CDRs) or hypervariable regions, that are present in VH and VL domains. The more highly conserved portions of V domains are called the framework (FR) regions.
- CDRs complementarity determining regions
- FR framework regions.
- Each VH and VL domain typically comprises four FR regions, largely adopting a ⁇ -sheet configuration, bonded to three CDRs, which form loops connecting, and in some cases forming part of, the ⁇ -sheet structure.
- the CDRs in each chain are held in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site (Kabat, E. A. et al, Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, MD (1987)).
- the C domains are not involved directly in antigen binding but exhibit various effector functions, such as opsonization, complement fixation and antibody-dependent cellular toxicity.
- an antigen-binding fragment of an Ig molecule including, Fab, Fab', F(ab') 2 , Fv or scFv fragments, all well-known in the art.
- Fab and F(ab') 2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et al, J. Nucl. Med. 2 ⁇ :316-325 (1983)).
- Fab fragments (and other forms of monovalent antibodies that have only a single antigen-binding site, have other known advantages, especially if it is preferred to avoid or limit intemalization of the antibody into Met-bearing cells in vivo or activation of Met and the ensuing signal transduction pathways.
- Fab, F(ab') , Fv and scFv fragments or forms of the antibodies useful in the present invention may be used for the detection, quantitation or isolation of Met proteins and the diagnosis or therapy of Met- expressing tumors in the same manner as an intact antibody.
- Conventional fragments are typically produced by proteolytic cleavage, using enzymes such as papain (for Fab fragments) or pepsin (for F(ab') 2 fragments).
- Fv fragments are described in (Hochman, J. et al. ,1973, Biochemistry 12:1130-1135; Sharon, J, et al, 1976, Biochemistry 15:1591-1594).
- scFv polypeptides include the hypervariable regions from the Ig of interest and recreate the antigen binding site of the native Ig while being a fraction of the size of the intact Ig (Skerra, A. et al. (1988) Science, 240: 1038-1041; Pluckthun, A. et al. (1989) Methods Enzymol. 178: 497-515; Winter, G. et al (1991) Nature, 349: 293-299); Bird et al, (1988) Science 242:423; Huston et al (1988) Proc. Natl Acad. Sci. USA 85:5879; U.S. Patents No. 4,704,692, 4,853,871, 4,94,6778, 5,260,203, 5,455,030. Also included as antibodies are diabodies and multispecific antibodies formed by combining more than one antigen-binding antibody fragment from antibodies of different specificity.
- a “monoclonal antibody or mAb” as used herein refers to an antibody that is part of a substantially, if not totally, homogeneous population of antibodies that are a product of a single B lymphocyte clone.
- mAbs are well known in the art and are made using conventional methods; see for example, Kohler and Milstein, Nature 256:495-491 (1975); U.S. Patent No. 4,376,110; Harlow, E. et al, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988); Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analyses, Plenum Press, New York, NY (1980); H.
- mAbs maybe produced recombinantly as well, e.g., according to U.S. Pat. No. 4.816,567.
- mAbs maybe derived from a single species, e.g., a murine mAb or a human mAb, or may be chimeric.
- the mAbs of the present invention are intended to include "chimeric" antibodies.
- a chimeric antibody is an Ig molecule wherein different parts of the molecule are derived from different animal species.
- An example is an Ig having a variable region derived from a murine mAb and a human Ig constant region.
- antigen-binding fragments such chimeric antibodies.
- Chimeric antibodies and methods for their production are known in the art. See, for example, Cabilly et al, Proc. Natl Acad. Sci. USA 81:3213-3211 (1984); Cabilly et al, U.S. Patents 4,816,567 (3/28/89) and 6,331,415 (12/18/01); Morrison et al, Proc. Natl.
- Preferred chimeric antibodies are "humanized" antibodies. Methods for humanizing non- human antibodies are well known in the art. Humanized forms of non-human (e.g.,, murine) antibodies are chimeric Igs, chains or fragments thereof (such as Fv, Fab, Fab', etc.,) which include minimal sequence derived from the non-human Ig.
- a human Ig recipient antibody receives residues from a CDR non-human species (donor or import antibody, e.g., mouse, rat, rabbit) replacing the recipient CDR with the donor CDR residues.
- Fv framework residues of the human Ig may be replaced by corresponding non- human residues.
- Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
- the humanized antibody will comprise substantially all of at least one, and typically two, V domains, in which all or substantially all of the CDR regions correspond to those of a non-human Ig and all or substantially all of the FR regions are those of the human Ig consensus sequence.
- the humanized antibody optimally also will comprise at least part of a human Ig C region (e.g., Fc). See, Jones et al, Nature 321:522-525 (1986); Reichmann et al, Nature 332:323-321 (1988); Presta, Curr. Op. Struct.
- V H and V L human V domains
- the choice of human V domains, (V H and V L ) to be used in making the humanized antibodies is important for reducing the antigenicity of the product when administered repeatedly to a human.
- the sequence of the V domain of a rodent antibody is screened against the entire library of known human Variable domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human FR for the humanized antibody (Sims et al, J. Immunol. 151:2296 (1993); Chothia et al, J.
- Another method uses a particular FR derived from the consensus sequence of all human antibodies of a particular subgroup of L or H chains. The same FR may be used for several different humanized antibodies (Carter et al, Proc. Natl. Acad. Sci. USA 89:4285 (1992); Presta et al, J. Immunol. 151:2623-2632 (1993)).
- humanized antibodies retain their (preferably high) binding affinity for the antigen and other favorable biological properties.
- humanized antibodies are designed by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional (3D) models of the parental and humanized sequences.
- 3D Ig models are commonly available and are known to those skilled in the art.
- Available computer programs illustrate and display probable 3D conformational structures of selected candidate Ig sequences. Inspection of these displays permits analysis of the likely role of certain amino acid residues in the functional capacity of the candidate Ig sequence, hi this way, FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic is achieved.
- the CDR residues are directly and most substantially involved in influencing antigen binding (e.g.,, WO 94/04679).
- transgenic animals e.g., mice
- J H antibody H chain joining region
- the homozygous deletion of the antibody H chain joining region (J H ) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production.
- Transfer of the human germ-line Ig gene array into such germ-line mutant mice will result in the production of human antibodies upon antigen challenge (Jakobovits et al, Proc. Natl. Acad. Sci. USA 0:2551-255 (1993); Jakobovits et al Nature, 362:255-258 (1993); Bruggermann et al, Year in Immuno 7:33 (1993)).
- Human antibodies can also be produced in phage display libraries (Hoogenboom et al, J. Mol. Biol 222:381 (1991); Marks et al, J. Mol. Bio., 222:581 (1991)).
- the techniques of Cote et al and Boerner et al. are also available for the preparation of human mAbs (Cole et al, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al, J. Immunol, 147:86-95 (1991).
- chimeric molecules or fusion polypeptides involving the present mAb or antigen-binding fragments of domains thereof include those designed for an extended in vivo half-life. This may include first identifying the sequence and conformation of a "salvage receptor" binding epitope of an Fc region of an IgG molecule.
- a "salvage receptor binding epitope” refers here to an epitope or fragment of the Fc region of an IgG molecule of any isotype contributes to increasing the in vivo half-life of the particular IgG molecule (when compared to other Ig classes). Once this epitope is identified, the sequence of the mAb is modified to include the sequence and conformation of the identified binding epitope.
- the chimera is tested for longer in vivo half-life compared to the unmodfied Ig molecule or chain. If a longer half-life is not evident, the sequence is altered further to include the sequence and conformation of the identified binding epitope. Care is taken that the antigen- binding activity or other desired biological activity of this chimeric molecule is maintained.
- the salvage receptor binding epitope generally constitutes a region corresponding to all or part of one or two loops of a Fc domain; preferably this sequence is "grafted" in an analogous position in the anti-Met antibody fragment.
- the epitope is taken from the IgG CH 2 domain and transferred to one or more of the CH l5 CH 3 , or V H region of the anti-Met antibody.
- the epitope from the CH 2 domain is transferred to the C L or the V domain of the anti-Met antibody fragment.
- Another chimeric molecule intended herein comprises the anti-Met antibody chain or fragment fused to an Ig constant domain or to an unrelated ( heterologous) polypeptide such as albumin.
- Such chimeras can be designed as monomers, homomultimers or heteromultimers, with heterodimers prefened.
- the chimera comprises a anti-Met antibody fragment fused to albumin.
- Such chimeras may be constructed by inserting the entire coding region of albumin into a plasmid expression vector.
- the DNA encoding the antibody chain or fragment can be inserted 5' to the albumin coding sequence, along with an insert that encodes a linker , e.g., Gly (Lu et al, FEBS Lett 356:56-59 (1994)).
- the chimera can be expressed in desired mammalian cells or yeast. hi general, these various chimeric molecules can be constructed in a fashion similar to more conventional chimeric antibodies in which a Variable domain from one antibody is substituted for the V domain of another antibody.
- Diabodies are small antibody fragments with two antigen binding sites, which fragments comprise V H domain bonded to a V domain in the same polypeptide chain (V H -V L ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen binding sites. Diabodies are described in further detail, for example, in EP404,097; WO 93/11161; and Hollinger et al, Proc. Natl. Acad. Sci, 90:6444-6448 (1993).
- An anti-idiotypic (anti-Id) antibody is an antibody which recognizes unique determinants generally associated with the antigen-binding site of another antibody.
- An anti-Id antibody can be prepared by immunizing an animal of the same species and genetic type (e.g., mouse strain) as the source of the mAb with the mAb to which an anti-Id is being prepared. The immunized animal will recognize and respond to the idiotypic epitopes of the immunizing antibody by producing an antibody to these idiotypic determinants (the anti-Id antibody).
- the anti-Id antibody may also be used as an "immunogen" to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody.
- the anti-anti-Id may be epitopically identical to the original mAb which induced the anti-Id.
- Anti-Id mAbs thus have their own idiotypic epitopes, or "idiotopes" structurally similar to the epitope if interest, such as a Met epitope.
- Antibody Functional Derivatives and Chemically Modified Antibodies Chemical, including, covalent modifications of anti-Met antibodies are within the scope of this invention.
- One type of modification is introduced into the molecule by reacting targeted amino acid residues with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues.
- Derivatization with bifunctional agents is useful for crosslinking the antibody (or fragment or derivative) to a water-insoluble support matrix or surface for use in a purification method (described below).
- Commonly used crosslinking agents include, e.g., l,l-bis(diazo- acetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido- 1,8-octane.
- Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate create photoactivatable intermediates that can crosslink when inadiated with light.
- Reactive water- insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are used in protein immobilization.
- proteins in which the native glycosylation pattern of the polypeptide have been altered This means deletion of one or more carbohydrate moieties and/or adding one or more glycosylation sites that are not present in the native polypeptide chains.
- Protein glycosylation is typically N-linked (attached to an Asp side chain) or O-linked (attached to a hydroxyamino acid, most commonly Ser or Thr; possibly 5-hydroxyPro or 5-hydroxyLys).
- the tripeptide Asp-Z-Ser and Asp-Z-Thr are recognition sequences for enzymatic attachment of the carbohydrate moiety to the Asp side chain. The presence of either of these sequences creates a potential N-glycosylation site.
- O-linked glycosylation usually involves binding of N-acetylgalactosamine, galactose, or xylose.
- Addition of glycosylation sites to the polypeptide may be accomplished by altering the native amino acid sequence to include e one or more of the above-described tripeptide sequences (for N-linked glycosylation sites) or addition of, or substitution by, one or more Serine or Threonine (for O- linked glycosylation sites).
- the amino acid sequence may be altered through changes at the DNA level, e.g., by mutating the DNA encoding the Ig polypeptide chain at preselected bases to generate codons that encode the desired amino acids. See, for example U.S. Pat. No. 5,364.934.
- the sugar(s) may be attached to (a) Arginine and His, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of Cys, (d) free hydroxyl groups such as those of Serine, Thr, or hydroxyPro, (e) aromatic residues such as those of Phe, Tyr, or Trp, or (f) the amide group of Gin.
- Removal of existing carbohydrate moieties may be accomplished chemically or enzymatically or by mutational substitution of codons (as described above).
- Chemical deglycosylation is achieved, for example, by exposing the polypeptide to trifluoromethanesulfonic acid, or an equivalent compound cleaves most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. See: Hakimuddin et al, Arch. Biochem. Biophys., 259:52 (1987); Edge et al, Anal Biochem. 118:131 (1981).
- Glycosylation at potential glycosylation sites may be prevented by the use of the tunicamycin (Duskin et al, JBiol Chem, 257:3105 (1982) which blocks formation of N- glycosidic linkages.
- Another type of chemical modification of the present antibodies comprises bonding to any one of a number of different nonproteinaceous polymers, such as polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner described in U.S. Patents No. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 and 4,179,337 and WO93/00109.
- the antibodies or fragments of the present invention may be used to quantitatively or qualitatively detect the presence of Met in a cellular or other biological sample. For example, it may be desired to monitor the level of Met in the circulation or in the tissues of a subject receiving a therapeutic dose or form of the mAb.
- the antibodies (or fragments thereof) useful in the present invention may be employed histologically to detect the presence of Met-bearing tumor cells.
- the present invention is directed in particular to a number of useful mAbs reactive against various epitopes of the Met, of HGF or the Met-HGF complex. Most preferred are mAbs specific for Met, particularly those specific for an epitope on the Met ECD.
- the mAbs and combinations of the present invention, along with various names used for each mAb (some being abbreviations of longer designations) are shown in Table 1, below.
- the hybridomas producing these mAbs have been deposited in the American Type Culture Collection (ATCC) prior to the filing of the present application. Their ATCC Patent Deposit Designations (or accession numbers), are provided in Table 1.
- the I-mAb mixture was injected intravenously (l. v.) into mice beanng one of several types of tumor.
- One class of tumors grew by autocrine stimulation of hMet by hHGF which they expressed.
- Other tumors grew by autocrine-paracrine stimulation of mMet by mHGF (murine Met and murine HGF).
- the present invention also includes microscopic imaging techniques combined with immunochemical and biochemical analyses to understand the molecular bases of the observed reactions, e.g., determining the relative contributions of such parameters as total cellular Met levels, surface access of Met to mAbs, the state of Met activation, and rates of receptor turnover, to the imaging characteristics of Met-expressing tumors in vivo.
- Anti-hMet mAbs alone, preferably Met3 or Met5, a combination of anti-hMet mAbs, e.g., Met3 + Met5, or a combination of one or more anti-hMet mAbs with anti-hHGF mAbs, offer a novel approach in the imaging by, for example, radioimmunoscintigraphy (as well as for immunotherapy and radioimmunotherapy) of neoplasms in mammals, preferably humans.
- mAbs or derivatives thereof have received clinical approval for radioimmunoscintigraphy or radioimmunotherapy. All these target neoplasms based on the cells of origin of the tumor (e.g., carcinoma, sarcoma., lymphoma, etc.).
- the present invention targets neoplasms based on the inappropriate expression of Met and/or hHGF, which has been correlated with poor prognosis in a wide range of human solid tumors not limited by tissue of origin, hi neoplastic cells the abenant expression of Met and HGF leads to emergence of an invasive/metastatic phenotype.
- Anti-hMet mAbs optionally in combination with anti-hHGF mAbs offer a novel approach to the radioimmunoscintigraphy to immunotherapy and radioimmunotherapy of neoplasms in animals and in humans.
- mAbs or derivatives thereof that have received clinical approval for radioimmunoscintigraphy or radioimmunotherapy (e.g. , Bexxar®, OncoScint®, ProstaScint®, Verluma®, CEAScan®, Zevalin®) all target neoplasms based on the tumor's cells of origin (e.g., carcinoma, sarcoma., lymphoma, etc.).
- anti-hMet mAbs alone or in combination with anti-hHGF mAbs target neoplasms based on the inappropriate expression of Met and/or hHGF, which has been correlated with poor prognosis in a wide range of human solid tumors, h neoplastic cells the abenant expression of Met and HGF leads to emergence of an invasive/metastatic phenotype.
- radiolabeled mAbs are effective at detecting Met- and/or HGF/SF-expressing tumors in humans.
- the present mAbs can be detectably labeled and used, for example, to detect Met on the surface or in the interior of a cell. Such approaches are exemplified below.
- the fate of the mAb during and after binding can be followed in vitro or in vivo by using the appropriate method to detect the label.
- the labeled mAb may be utilized in vivo for diagnosis and prognosis
- diagnosis and prognosis The term "diagnostically labeled" means that the mAb has attached to it a diagnostically detectable label. There are many different labels and methods of labeling known to those of ordinary skill in the art.
- Examples of the types of labels which can be used in the present invention include radioactive isotopes, paramagnetic isotopes, and compounds which can be imaged by positron emission tomography (PET).
- PET positron emission tomography
- Those of ordinary skill in the art will know of other suitable labels for binding to the mAbs used in the invention, or will be able to ascertain such, by routine experimentation. A number of such classes of diagnostic labels are disclosed below. Diagnostically-labeled (e.g., radiolabeled) mAbs are effective at detecting Met- and/or HGF-expressing human tumors in animal models and are therefore expected to be similarly effective in humans bearing such tumors.
- Suitable detectable labels for diagnosis and imaging include radioactive, fluorescent, fluorogemc, chromogenic, or other chemical labels.
- Useful radiolabels, which are detected simply by gamma counter, scintillation counter, PET scanning or autoradiography include 3 H, 1241, 125 1, 131 1, 35 S and 14 C
- 131 I is a useful therapeutic isotope (see below).
- Common fluorescent labels include fluorescein, rhodamine, dansyl, phycoerythrin, phycocyanin, allophycocyanin, ⁇ -phthaldehyde and fluorescamine.
- the fluorophore such as the dansyl group, must be excited by light of a particular wavelength to fluoresce. See, for example, Haugland, Handbook of Fluorescent Probes and Research Chemicals, Sixth Ed., Molecular Probes, Eugene, OR., 1996).
- the long wavelength rhodamines which are basically Rhodamine GreenTM derivatives with substituents on the nitrogens, are among the most photostable fluorescent labeling reagents known.
- This group includes the tetramethylrhodamines, X-rhodamines and Texas RedTM derivatives.
- Other prefened fluorophores for derivatizing the peptide according to this invention are those which are excited by ultraviolet light. Examples include cascade blue, coumarin derivatives, naphthalenes (of which dansyl chloride is a member), pyrenes and pyridyloxazole derivatives.
- semiconductor nanocrystals comprising, for example, cadmium sulfate (Bruchez, M.
- the amino groups of a anti-Met mAb are allowed to react with a reagent that yields a fluorescent product, for example, fluorescamine, dialdehydes such as o- phthaldialdehyde, naphthalene-2,3-dicarboxylate and anthracene-2,3-dicarboxylate.
- a reagent that yields a fluorescent product for example, fluorescamine, dialdehydes such as o- phthaldialdehyde, naphthalene-2,3-dicarboxylate and anthracene-2,3-dicarboxylate.
- NBD 7-nitrobenz- 2-oxa-l,3-diazole
- the mAbs can also be labeled for detection using fluorescence-emitting metals such as
- Radionuchdes may be bound to the mAb either directly or indirectly using a chelating agent such as DTPA and EDTA. Examples of such radionuchdes are 99 Tc, 123 1, 125 1, 131 I, m In, 97 Ru, 67 Cu, 67 Ga, 68 Ga, 72 As, 89 Zr, 90 Y and 201 T1.
- the amount of labeled mAb needed for detectability in diagnostic use will vary depending on considerations such as age, condition, sex, and extent of disease in the patient, contraindications, if any, and other variables, and is to be adjusted by the individual physician or diagnostician. Dosage can vary from 0.01 mg/kg to 100 mg/kg.
- the mAbs can also be made detectable by coupling them to a phosphorescent or a chemilu inescent compound.
- the presence of the chemiluminescent-tagged peptide is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
- chemiluminescers are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
- a bioluminescent compound may be used to label the peptides. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction.
- the presence of a biolummescent protein is determined by detecting the presence of luminescence.
- Important biolummescent compounds for purposes of labeling are luciferin, luciferase and aequorin.
- colorimetric detection is used, based on chromogenic compounds which have, or result in, cliromophores with high extinction coefficients.
- In situ detection of the labeled mAb may be accomplished by removing a histological specimen from a subject and examining it by microscopy under appropriate conditions to detect the label.
- histological methods such as staining procedures
- any of a wide variety of histological methods can be modified in order to achieve such in situ detection.
- the type of detection instrument available is a major factor in selecting a radionuclide.
- the radionuclide chosen must have a type of decay, which is detectable by a particular instrument, hi general, any conventional method for visualizing diagnostic imaging can be utilized in accordance with this invention.
- a radionuclide used for in vivo imaging does not emit particles, but produces a large number of photons in a 140-200 keV range, which may be readily detected by conventional gamma cameras.
- a preferred diagnostic method is radioimmunoscintigraphic analysis, which is preferably performed in a manner that results in serial total body gamma camera images and allows determination of regional activity by quantitative "region-of-interest” (ROI) analysis. Examples are provided below.
- ROI region-of-interest
- every solid human tumor that is biopsied or excised can be intenogated routinely by immunohistochemistry to characterize its Met-expression status. All patients with Met-positive tumors would then undergo a Met-directed nuclear imaging study to disclose residual or clinically occult lesions and assess their abundance of Met, or to document that none are evident.
- Any patient with residual or newly disclosed lesions could be evaluated by provocative diagnostic MRI and/or ultrasonography to determine the physiologic responsiveness of their tumors, and an appropriate therapy regimen (chemotherapy, immunotherapy, radioimmunotherapy) would then be devised. Finally, provocative functional imaging or Met-directed nuclear imaging would be used to monitor changes in Met abundance and activity in response to therapy.
- tumors growing in an autocrine manner due to interaction of hHGF and hMet took up and cleared the 125 I-mAb mixture more rapidly than did tumors expressing mHGF, mMet or both, h tumors with hHGF/hMet, the ratio of mean tumor radioactivity to total body radioactivity was >0.3 one day postinjection.
- 1 ⁇ expression is achieved using a radioiodinated ( I) mixture of mAbs that are reactive with the ligand (HGF) -receptor (Met) pair.
- I radioiodinated
- the present methods offer newly diagnosed cancer patients a novel sort of "metastatic risk stratification” that uses noninvasive means to assess as high or low the probability that a given tumor will subsequently invade or metastasize, without any dependence on the tumor's "tissue" of origin. Such information improves our ability to design appropriate monitoring and therapy protocols on an individual patient basis. Very large number of patients can benefit from the present invention of using anti-hMet mAbs for diagnostic imaging and for immunotherapy and/or radioimmunotherapy.
- the present inventors calculated that, for example, if only half of all patients in Michigan with newly discovered solid tumors were to undergo imaging using the present methods - with either anti-hMet mAb and/or anti-hHGF mAb -as part of their staging and metastatic risk assessment, that number, >20,000 cases per year, would far exceed the actual annual mcidence of any single type of cancer in Michigan, and would far exceed the combined clinical volume currently served by all other FDA-approved mAbs.
- In vivo imaging may be used to detect occult metastases which are not observable by other methods.
- the expression of Met can be conelated with progression of diseases in cancer patients such that patients with late stage cancer have higher levels of Met expression (or HGF binding) in both their primary tumors and metastases.
- Met- or HGF-targeted imaging could be used to stage tumors non-invasively or to detect another disease which is associated with the presence of increased levels of Met/HGF.
- the compositions of the present invention may be used in diagnostic, prognostic or research procedures in conjunction with any appropriate cell, tissue, organ or biological sample of the desired animal species.
- biological sample any fluid or other material derived from the body of a normal or diseased subject, such as blood, serum, plasma, lymph, urine, saliva, tears, cerebrospinal fluid, milk, amniotic fluid, bile, ascites fluid, pus and the like. Also included within the meaning of this term is a organ or tissue extract and a culture fluid in which any cells or tissue preparation from the subject has been incubated.
- the labeled mAbs are administered systemically, e.g., by injection or infusion.
- injection or infusion may be by any known route, preferably intravenous injection or infusion, subcutaneous injection, intramuscular, intracranial or intrathecal injection or infusion, or intraperitoneal administration.
- injectables can be prepared in conventional forms, either as solutions or suspensions, solid forms
- compositions can be used with domestic and commercial animals, including birds and more preferably mammals, as well as humans.
- the antibody compositions of this invention also additional utility to the therapeutic or in vivo diagnostic uses.
- the antibody compositions are useful for detecting overexpression of Met in specific cells and tissues. (This can also serve as a diagnostic tool.)
- Various immunoassay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases. See, for example, Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158).
- the antibodies used in this manner may be detectably labeled with a detectable label that produces, either directly or indirectly, a detectable signal.
- Convenient labels for in vitro uses include radioisotopes, for 3 H,
- a prefened way to label the antibody or fragment is by linking it to an enzyme and using it in an enzyme immunoassay (EIA), or enzyme-linked immunosorbent assay (ELISA).
- EIA enzyme immunoassay
- ELISA enzyme-linked immunosorbent assay
- Enzymes which are commonly used for this purpose include horseradish peroxidase, alkaline phosphatase, glucose-6-phosphate dehydrogenase, malate dehydrogenase, staphylococcal nuclease, ⁇ -V-steroid isomerase, yeast alcohol dehydrogenase, -glycerophosphate dehydrogenase, triose phosphate isomerase, asparaginase, glucose oxidase, ⁇ -galactosidase, ribonuclease, urease, catalase, glucoamylase and acetylcholinesterase.
- the antibodies of the present invention are also useful as affinity ligands for binding to Met or to cells expressing Met in assays, preparative affinity chromatography and solid phase separation of molecules from a mixture that includes Met. Such antibody compositions may also be used to identify, enrich, purify or isolate cells to which the antibodies bind, using flow cytometric and/or solid phase methodologies.
- the mAb may be immobilized using conventional methods, e.g.
- the mAbs of the invention may be immobilized by any other method which is capable of immobilizing these compounds to a solid phase for the indicated purposes. See, for example Affinity Chromatography: Principles and Methods (Pharmacia LKB Biotechnology).
- one embodiment is a composition
- a composition comprising a mAb or mixture thereof, as described herein, bound to a solid support or a resin.
- the compound may be bound directly or via a spacer, preferably an aliphatic chain having about 2-12 carbon atoms.
- solid phase or “solid support” or “carrier” is intended any support or canier capable of binding the mAb or derivative.
- Well-known supports, or carriers, in addition to Sepharose ® or Agarose ® described above are glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses such as nitrocellulose, polyacrylamides, polyvinylidene difluoride, other agaroses, and magnetite, including magnetic beads.
- the carrier can be totally insoluble or partially soluble.
- the support material may have any possible structural configuration so long as the coupled molecule is capable of binding to receptor material.
- the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube or microplate well, or the external surface of a rod.
- the surface may be flat such as a sheet, test strip, bottom surface of a microplate well, etc.
- compositions of the invention include all of those compounds described above, as well as the pharmaceutically acceptable salts of these compounds.
- a composition of this invention may be active er se, or may act as a "pro-drug" that is converted in vivo to the active form.
- Effective dosages and schedules for administering the present compositions antagonist may be determined empirically; making such determinations is within the skill in the art.
- the effective dosage of the mAb composition will vary depending on, for example, the species of subject being treated, the route of administration, the particular type of mAb preparation or construct being used and any other drugs or agents being administered to the subject mammal.
- Guidance in selecting appropriate doses of mAbs is found in the literature on therapeutic uses of antibodies, e.g., Handbook of Monoclonal Antibodies, S. Ferrone et al, eds., Noges Publications, Park Ridge, NJ (1985), particularly chap. 22 and pp.
- a typical daily dosage of the therapeutic mAb compositions might range between about 1 ⁇ g and about 100 mg per kg of body weight, depending on the factors mentioned above.
- the present mAb composition is administered to a subject in combination with an effective amount of one or more other therapeutic agents or in conjunction with another therapeutic modality such as radiotherapy.
- Therapeutic agents contemplated include anticancer chemotherapeutics, immunoadjuvants and biological products such as immunostimulatory cytokines.
- Drugs intended for use in the combination therapies of the present invention include any known in the art, such as doxorubicin, 5-fluorouracil, cytosine arabinoside (Ara-C), cyclophosphamide, thiotepa, busulfan, Taxol, methotrexate, cisplatin, carbo-platin, melphalan, vinblastine, etc..
- the antibody composition may be administered before, after or concunent with one or more chemo- or biotherapeutic agents.
- the amount of the antibody composition and the conventional drug to be used together depend, for example, on the type of drug, the nature and extent of the tumor or cancer being treated, the scheduling and the respective routes of administration. Determination of precise doses are determined empirically and based on known responses to the conventional or better-known agents, h general, the dose would generally be less than if each of the antibody composition and conventional drug were administered individually.
- the subjects condition and the state of the tumor or cancer are be monitored in various conventional ways.
- the tumor mass may be monitored by physical means(including palpation), by standard x-ray and other radiographic techniques, and/or by using the novel diagnostic methods and compositions described herein.
- the compounds of the invention, as well as the pharmaceutically acceptable salts thereof, may be incorporated into convenient dosage forms, such as capsules, impregnated wafers, tablets or injectable preparations.
- Solid or liquid pharmaceutically acceptable carriers may be employed.
- Injectables can be prepared in conventional forms, either as solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
- Solid carriers include starch, lactose, calcium sulfate dihydrate, tena alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid.
- Liquid carriers include syrup, peanut oil, olive oil, saline, water, dextrose, glycerol and the like.
- the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- a liquid carrier When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., a solution), such as an ampoule, or an aqueous or nonaqueous liquid suspension.
- sterile injectable liquid e.g., a solution
- an ampoule or an aqueous or nonaqueous liquid suspension.
- Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid.
- Liquid carriers include syrup, peanut oil, olive oil, saline, water, dextrose, glycerol and the like.
- the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., a solution), such as an ampoule, or an aqueous or nonaqueous liquid suspension.
- sterile injectable liquid e.g., a solution
- an ampoule e.g., an ampoule
- aqueous or nonaqueous liquid suspension e.g., aqueous or nonaqueous liquid suspension.
- the pharmaceutical preparations are made following conventional techniques of pharmaceutical chemistry involving such steps as mixing, granulating and compressing, when necessary for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired products for oral, parenteral, topical, transdermal, intravaginal, intrapenile, intranasal, intrabronchial, intracranial, intraocular, intraaural and rectal administration.
- the pharmaceutical compositions may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and so forth.
- the pharmaceutical composition may be administered topically or transdermally, e.g., as an ointment, cream or gel; orally; rectally; e.g., as a suppository, parenterally, by injection or continuously by infusion; intravaginally; intrapenilely; intranasally; intrabronchially; intracranially, intraaurally; or intraocularly.
- sprayable aerosol preparations wherein the composition, preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant.
- the aerosol preparations can contain solvents, buffers, surfactants, perfumes, and/or antioxidants in addition to the compounds of the invention.
- an effective amount of the compound for the preferred topical applications, especially for humans, it is prefened to administer an effective amount of the compound to an affected area, e.g., skin surface, mucous membrane, eyes, etc.
- an affected area e.g., skin surface, mucous membrane, eyes, etc.
- This amount will generally range from about 0.001 mg to about 1 g of a given antibody per application, depending upon the area to be treated, the severity of the symptoms, and the nature of the topical vehicle employed.
- compositions of the invention may comprise, in addition to the labeled antibodies, one or more additional anti-tumor agents, such as mitotic inhibitors, e.g., vinblastine; alkylating agents, e.g., cyclophosphamide; folate inhibitors, e.g., methotrexate, piritrexim or trimetrexate; antimetabolites, e.g., 5-fluorouracil and cytosine arabinoside; intercalating antibiotics, e.g., adriamycin and bleomycin; enzymes or enzyme inhibitors, e.g., asparaginase, topoisomerase inhibitors such as etoposide; or biological response modifiers, e.g., interferons or interleukins.
- additional anti-tumor agents such as mitotic inhibitors, e.g., vinblastine; alkylating agents, e.g., cyclophosphamide; folate inhibitors,
- compositions comprising any known cancer therapeutic in combination with the labeled antibodies disclosed herein are within the scope of this invention.
- the pharmaceutical composition may also comprise one or more other medicaments to treat additional symptoms for which the target patients are at risk, for example, anti-infectives including antibacterial, anti-fungal, anti-parasitic, anti-viral, and anti-coccidial agents.
- the antibodies described herein are "therapeutically conjugated” or “therapeutically labeled” (terms which are intended to be interchangeable) and used to deliver a therapeutic agent to the site to which the antibodies home and bind, such as sites of primary tumor or tumor metastasis.
- therapeutically conjugated means that the protein is conjugated to another therapeutic agent that is physically directed to a "component" of tumor growth or invasion.
- Examples of useful therapeutic radioisotopes include 7 Sc, 67 Cu, 90 Y, 109 Pd, 125 1, 131 1, 186 Re, 188 Re, 199 Au, 211 At, 212 Pb and 217 Bi. These atoms can be conjugated to the polypeptide directly, indirectly as part of a chelate, or, in the case of iodine, indirectly as part of an iodinated Bolton-Hunter group.
- Prefened doses of the radionuclide conjugates are a function of the specific radioactivity to be delivered to the target site which varies with tumor type, tumor location and vascularization, kinetics and biodistribution of the polypeptide carrier, energy of radioactive emission by the nuclide, etc.
- Those skilled in the art of radiotherapy can readily adjust the dose of the labeled protein in conjunction with the dose of the particular nuclide to effect the desired therapeutic benefit without undue experimentation.
- NCT boron neutron capture therapy
- a boronated antibody is delivered to a desired target site, such as a tumor, most preferably an intracranial tumor
- a desired target site such as a tumor, most preferably an intracranial tumor
- Barth, R.F., Cancer Invest. 74:534-550 (1996); Mishima, Y. (ed.), Cancer Neutron Capture Therapy, New York: Plenum Publishing Corp., 1996; Soloway, A.H., et al, (eds), J. Neuro-Oncol 33:1-188 (1997).
- the stable isotope 10 B is inadiated with low energy ( ⁇ 0.025 eV) thermal neutrons, and the resulting nuclear capture yields ⁇ particles and 7 Li nuclei which have high linear energy transfer and respective path lengths of about 9 and 5 ⁇ m.
- This method is predicated on 10 B accumulation in the tumor with lower levels in blood, endothelial cells and normal tissue (e.g., brain).
- Such delivery has been accomplished using epidermal growth factor (Yang. W. et al, Cancer Res 57:4333-4339 (1997).
- gadolinium specifically 157 Gd appears to be particularly advantageous for use in NCT with the present antibodies. It has recently been reported
- Gd-NCT may increase the chance for photons to hit tumor cells and for electrons to damage these cell locally and intensively. Another advantage is that Gd has long been used as a MRI imaging diagnostic agent.
- Gd-NCT with MRI diagnosis by using the Gd-loaded dosage forms of the present antibodies.
- a prefened fonn of Gd for labeling the antibodies of this invention for use in Gd-NCT is gadopentetic acid (Gd- DTPA).
- Other therapeutic agents which can be coupled to the antibodies according to the method of the invention are drugs, prodrugs, enzymes for activating pro-drugs, photosensitizing agents, gene therapeutics, antisense vectors, viral vectors, lectins and other toxins.
- the therapeutic dosage administered is an amount that is therapeutically effective, as is known to or readily ascertainable by those skilled in the art.
- the dose is also dependent upon the age, health, and weight of the recipient, kind of concunent treatment(s), if any, the frequency of treatment, and the nature of the effect desired, such as, for example, anti-inflammatory effects or anti-bacterial effect.
- Lectins are proteins, commonly derived from plants, that bind to carbohydrates. Among other activities, some lectins are toxic. Some of the most cytotoxic substances known are protein toxins of bacterial and plant origin (Frankel, A.E. et al, Ann. Rev. Med. 37:125-142 (1986)). These molecules binding the cell surface and inhibit cellular protein synthesis. The most commonly used plant toxins are ricin and abrin; the most commonly used bacterial toxins are diphtheria toxin and Pseudomonas exotoxin A. In ricin and abrin, the binding and toxic functions are contained in two separate protein subunits, the A and B chains.
- the ricin B chain binds to the cell surface carbohydrates and promotes the uptake of the A chain into the cell. Once inside the cell, the ricin A chain inhibits protein synthesis by inactivating the 60S subunit of the eukaryotic ribosome Endo, Y. et al, J. Biol. Chem. 262: 5908-5912 (1987)).
- Other plant derived toxins which are single chain ribosomal inhibitory proteins, include pokeweed antiviral protein, wheat germ protein, gelonin, dianthins, momorcharins, trichosanthin, and many others (Strip, F. et al, FEBS Lett. 195:1-8 (1986)).
- Diphtheria toxin and Pseudomonas exotoxin A are also single chain proteins, and their binding and toxicity functions reside in separate domains of the same protein chain with full toxin activity requiring proteolytic cleavage between the two domains.
- Pseudomonas exotoxin A has the same catalytic activity as diphtheria toxin.
- Ricin has been used therapeutically by binding its toxic ⁇ -chain, to targeting molecules such as antibodies to enable site-specific delivery of the toxic effect.
- Bacterial toxins have also been used as anti-tumor conjugates.
- a toxic peptide chain or domain is conjugated to an antibody of this invention and delivered in a site-specific manner to a target site where the toxic activity is desired, such as a metastatic focus.
- Methods for chemical conjugation of toxins to antibodies or other ligands and recombinant production of toxin-containing fusion proteins are known in the art (e.g., Olsnes, S. et al, Immunol. Today 70:291-295 (1989); Vitetta, E.S. et al, Ann. Rev. Immunol 3:197-212 (1985)).
- Cytotoxic drugs that interfere with critical cellular processes including DNA, RNA, and protein synthesis have been conjugated to antibodies and subsequently used for in vivo therapy.
- Such drugs including, but not limited to, daunorubicin, doxorubicin, methotrexate, and mitomycin C are also coupled to the present antibodies and used therapeutically in this form.
- photosensitizers maybe coupled to the present antibodies for delivery directly to a tumor.
- the methods of this invention may be used to inhibit tumor growth and invasion in a subject. By inhibiting the growth or invasion of a tumor, the methods are intended to inhibit tumor metastasis as well.
- a mammalian subject preferably a human, is administered an amount of a therapeutic antibody composition of this invention in an amount effective to inhibit tumor growth, invasion or metastasis.
- the compound or pharmaceutically acceptable salt thereof is preferably administered in the form of a pharmaceutical composition as described above.
- Doses of the compounds preferably include pharmaceutical dosage units comprising an effective amount of the antibody or combination of antibodies.
- an effective amount is meant an amount sufficient to achieve a steady state concentration in vivo which results in a measurable reduction in any relevant parameter of disease and may include growth of primary or metastatic tumor, or a measurable prolongation of disease-free interval or of survival.
- a reduction in tumor growth in 20 % of patients is considered efficacious (Frei III, E., The Cancer Journal 3:127-136 (1997)).
- an effect of this magnitude is not considered to be a minimal requirement for the dose to be effective in accordance with this invention.
- an effective dose is preferably 10-fold and more preferably 100-fold higher than the 50% effective dose (ED 50 ) of the composition in an in vivo assay as described herein.
- the amount of active compound to be administered depends on the precise antibody or combination selected, the disease or condition, the route of administration, the health and weight of the recipient, the existence of other concurrent treatment, if any, the frequency of treatment, the nature of the effect desired, for example, inhibition of tumor metastasis, and the judgment of the skilled practitioner.
- a preferred dose for treating a subject, preferably mammalian, more preferably human, with a tumor is an amount up to about 100 milligrams of total antibody protein per kilogram of body weight.
- a typical single dosage is between about 1 ng and about lOOmg/kg body weight.
- dosages in the range of about 0.01-20% concentration (by weight) of the compound, preferably 1-5%, are suggested.
- a total daily dosage in the range of about 0.1 milligrams to about 7 grams is prefened for intravenous administration.
- Effective doses and optimal dose ranges may be determined in vitro or in murine models using the methods described herein.
- a rabbit polyclonal antiserum with neutralizing activity against HGF/SF (1 ⁇ l/well) was included as a Met-neutralizing control. Following overnight incubation at 37°C, cells were then stained with 0.5% crystal violet in 50% ethanol v/v for 10 minutes at room temperature, and scattering was viewed using a light microscope.
- Urokinase Plasminosen Activator-Plasmin proteolytic assay HGF stimulation of cells expressing Met induces expression of the serine protease urokinase (uPA) and its receptor (uPAR). uPA then cleaves plasminogen to the broader specificity protease plasmin. In this assay, we supply extra plasminogen to amplify the production of plasmin, and we also supply Chromozyme PL as a colorimetric substrate for plasmin. The process results in a colored cleavage product of Chromozyme PL, which can be quantified spectrophotometrically at 405 nm.
- mAbs are added at various concentrations alone or in the presence of 10 units HGF; control wells include no-HGF/no-mAb, HGF without antibody, and HGF in the presence of neutralizing anti-HGF antibodies.
- the use of anti-hMet mAb Met3 in combination with a neutralizing mixture of anti-HGF mAbs for imaging Met- and HGF-expressing tumors in vivo is described in detail in the Examples.
- Articles of Manufacture and Kits The invention also provides articles of manufacture and kits containing compositions useful for diagnosing or imaging Met-positive tumors, for treating such tumors, and for detecting, quantitating or purifying Met.
- the article of manufacture comprises a container with a label. Suitable containers include, for example, bottles, vials, and test tubes.
- the containers may be formed from a variety of materials such as glass or plastic.
- the container holds an active agent(s) which is a composition comprising one or more mAbs according to the invention, either anti-Met antibodies, or a combination of anti-Met and anti-HGF antibodies.
- the label on the container indicates that the composition is used for diagnosing, monitoring or for treating cancer, as the case may be, or preferably for diagnosing, monitoring or treating particular types of cancer or tumors that express Met or for which Met levels or turnover is diagnostic or prognostic or an effective target for therapy.
- the label indicates that the composition is useful for detecting, quantifying or purifying Met, and may also indicate directions for either in vivo or in vitro use, such as those described above.
- the kit of the invention comprises the container described above and a second container comprising a buffer or other reagent(s).
- the kit may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
- the kit may also contain another anticancer therapeutic agent, such as a chemotherapeutic drug or drugs.
- 125 I was purchased as Nal (480-630 mBq (13-17 mCi) per ⁇ g iodine) from Amersham Corp. (Arlington Heights, IL).
- C-28 rabbit polyclonal antibody reactive with the C-terminal portion of human Met was purchased from Santa Cruz Biotechnology, Inc.
- NTH 3T3 cells transformed with hHGF and hMet (Rong S et al, Cell Growth Differ. 1993;4:563-569) and M- 114 cells (NTH 3T3 cells transformed with mHGF and mMet).
- Cells were grown in DMEM containing 8% calf serum.
- SK-LMS-1 a human leiomyosarcoma cell line autocrine for hMet and hHGF (Jeffers M et al, Mol Cell Biol. 1996;! 6:1115-1125), was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS.
- DA3 a mouse mammary carcinoma cell line expressing mMet (Firon M et al, Oncogene 2000;19:2386-2391), was grown in DMEM supplemented with 10% FBS and antibiotics.
- HGF was prepared from SI 14 cells and mouse mAbs against this protein were produced by injecting Balb/C mice intraperitoneally (i.p.) with purified native HGF protein in complete Freund's adjuvant, followed by four additional injections of the purified protein in incomplete Freund's adjuvant. After one month, a final HGF injection was given i.p. and i.v. without adjuvant.
- mice were tested for their ability to neutralize HGF/SF in the MDCK cell scatter assay, a conventional, art-recognized assay of the biologic activity of HGF/SF.
- Spleen cells from animals whose sera had neutralizing antibodies were harvested and fused with P3X63AF8/653 myeloma cells using standard techniques three days after the final immunizing injection.
- Anti-Met mAbs mAbs against hMet were produced by injecting BALB/c mice intraperitoneally(i.p.) with 5xl0 6 121-1TH-14 cells (expressing hMet) in 0.5ml phosphate buffered saline (PBS), followed by three additional injections of the same dose.. After one month, 10 7 Okajima cells in 0.5 ml PBS were injected i.p. into each mouse. Spleen cells, obtained four days after the final injection, were fused with P3X63AF8/653 myeloma cells using standard techniques.
- PBS phosphate buffered saline
- Hybridoma cells were screened for reactivity to hMet by ELISA using 96 well microplates coated with 0.5 ⁇ g/ml c-Met/Fc chimeric protein.
- c-Met/Fc is a fusion protein of the hMet ECD with human IgGi H chain (purchased from R & D Systems, catalog number: 358- MT) in coating buffer (0.2M Na 2 CO 3 /NaHCO 3 , pH 9.6, 50 ⁇ l per well) overnight at 4°C After blocking the wells with 200 ⁇ l of blocking buffer (PBS- 1% BSA) for 1 hr at room temperature or overnight at 4°C, 50 ⁇ l of hybridoma supernatant were added to wells for 1.5 hr at room temperature.
- PBS- 1% BSA blocking buffer
- S-l 14 cells and control parental NIH-3T3 cells in 8 well strips were fixed in either formaldehyde or acetone/methanol (1:1, v/v) for 10 min at room temperature, air dried for 10 min, and blocked with blocking buffer (PBS-1% BSA) for 30 min at room temperature.
- Purified anti-Met mAbs and control normal mouse IgG were diluted to 20 ⁇ g/ml with blocking buffer and added to either S-l 14 or control NIH 3T3 cells at 50 ⁇ l/well.
- IgG fractions were purified from hybridoma supematants by protein G affinity chromatography and were adjusted to a final concentration of 2 mg/ml in 0.25 sodium phosphate buffer, pH 6.8-7.0. The purified IgG fractions were stored frozen in small aliquots (50 ⁇ g) and thawed just prior to radioiodination.
- the final mAb mixture was radioiodinated according to instructions of the radionuclide supplier. Briefly, to 25 ⁇ g of mAb mixture in 0.1 ml of 0.25 M sodium phosphate (pH 6.8) was added 74 MBq (2.0 mCi; 20 ⁇ l) of 125 I as sodium iodide and 20 nmol (lO ⁇ l) of chloramine-T. The reactants were mixed and agitated gently for 90 sec at room temperature. The reaction was
- mice Just prior to each imaging session each mouse was given up to 13 mg/kg xylazine and 87 mg/kg ketamine s.c. in the interscapular region.
- mice Sedated mice were placed singly or in pairs on top of an inverted camera head with a protective layer over the collimator, and taped to the layer to maintain optimum limb extension, hnages of 125 I activity were acquired on a Siemens LEM Plus mobile camera with a low-energy, high-sensitivity collimator. Images were acquired over a period of 15 minutes, during which between 2 x 10 5 and 3 x 10 6 counts were acquired per total body image. Relative activity was detennined by computer-assisted region-of-interest (ROI) analysis for each tumor, for total body, and for appropriate background regions at each imaging time point. These data are expressed below as background- and decay-conected activity ratios. Graphical and statistical analysis of the converted data was performed with Microsoft Excel.
- ROI region-of-interest
- EXAMPLE 3 Image Analysis and Quantitation Serial total body gamma camera images of individual tumor-bearing mice were obtained between one hour and five days following i.v. injection of the 125 I-mAb mixture reactive with hHGF and hMet. See Figure 2. Activity was evident in the human tumors (SK-LMS-1 and S- 114, both of which express hHGF and hMet) as early as one hour postinjection and prominently thereafter.
- mice bearing human tumors cleared radioactivity more rapidly from the circulation than mice bearing murine tumors, as evidenced by their much lower levels of visceral radioactivity at three and five days postinj ection and more conspicuous thyroid activity (reflecting uptake of free radioiodine released from labeled mAbs).
- Tt mean ratio of tumor activity to total body activity (including thyroid), designated Tt: WBt
- Tt mean ratio of tumor activity to total body activity (including thyroid)
- WBt mean ratio of tumor activity to total body activity (including thyroid)
- Tt:Tlh mean retention of tumor-associated activity
- ROI results were expressed as activity ratios rather than as the more traditional "percent of injected activity (%IA) (Hay et al, supra) in order to minimize the effects of variations in the efficiency of i.v. injection of radiolabeled mAb on the data.
- %IA percent of injected activity
- the ratio of tumor activity to total body activity at one hour (Tlh:WBlh) closely approximates %IA for a tumor at one hour, and the ratio Tt:WBlh similarly approximates %IA for a tumor at time t.
- Murine tumors (M-l 14 and DA3) did not show significant activity above that of blood pool by one hour or 24 hours postinjection.
- tumors expressing hHGF and hMet in an autocrine manner
- Tumors expressing mHGF and/or mMet can also be imaged with the radioiodinated mAb mixture, presumably because of epitope crossreactivity.
- in vivo metabolism of the 125 I-mAb mixture by human and murine tumors differ in their kinetics as ' well by other quantitative criteria.
- the human tumors evaluated display rapid uptake and rapid clearance of the mAb mixture from the circulation, and constitute a significantly higher proportion of total body radioactivity at times ranging from one hour to five days postinjection than do the murine tumors. Indeed, such differences would be expected between high-affinity, high-capacity tumors and those with lower affinity for binding and lower capacity for metabolizing a given radiotracer.
- radiolabeled anti-Met mAbs should bind directly to Met molecules expressed on the tumor cell surface, while anti-HGF mAbs can either bind to HGF molecules concentrated locally in the immediate vicinity of a Met- expressing cell or can form a ternary complex with HGF and Met, effectively targeting Met- expressing tumor cells indirectly, for example, by binding to Met-bound HGF.
- This particular neutralizing mixture of anti-HGF mAbs may be involved in stabilizing Met so that an anti-Met mAb binds more readily or more avidly than it would otherwise. It is also possible that any one of the mAbs included in this mixture can alone be used to image these tumors.
- radiolabeled mAbs capable of detecting Met- and/or HGF-expressing tumors in humans, will be useful as a clinical tool to obtain for a given subject, his "metastatic risk stratification" based on noninvasive assessment of the likelihood (e.g., high or low) that a given tumor will later invade and metastasize. Such information will improve our ability to design appropriate monitoring and therapy protocols on an individual patient basis.
- 125 I was purchased as Nal (480-630 MBq; 13-17 mCi per ⁇ g iodine) from Amersham Corp. (Arlington Heights, IL).
- C-28 rabbit polyclonal antibody reactive with the C-terminal portion of human Met and H-235 rabbit polyclonal antibody reactive with ⁇ -tubulin were purchased from Santa Cruz Biotechnology, Inc.
- the Alexa 488-conjugated anti-mouse antibody was purchased from Molecular Probes. Immunodecoration reagents were purchased from Amersham Pharmacia BioTech. Cell lines and tumor induction
- S-l 14 cells are NIH 3T3 cells transformed with human HGF/SF and human Met (Rong et al, supra).
- SK-LMS-1/HGF cells are a human leiomyosarcoma cell line autocrine for human Met and human HGF/SF (Jeffers et al, supra).
- PC-3 cells are a human prostate carcinoma cell line.
- M14-Mel and SK-MEL-28 are human melanoma cell lines. All these cell lines were all maintained in DMEM supplemented with 10% FBS.
- mice at about six weeks of age received subcutaneous injections of S-l 14, SK-LMS-1/HGF, or PC-3 cell suspensions in the posterior aspect of their right thighs, or of melanoma cell suspensions in the right flank adjacent to the thigh. Each mouse received between 2xl0 5 and 5xl0 5 cells. Tumors developed for 1-6 weeks before imaging, reaching > 0.5 cm in greatest dimension by external caliper measurement. Mice were housed in small groups and given ad libitum access to mouse chow and drinking water under conditions approved by the institutional animal care committees. Analysis of Met expression by cell lines
- the cultured cell lines listed above were analyzed for relative abundance of Met by immunoblottmg with minor modifications of the procedures described previously (Webb, C.P. et al, 2000, Cancer Res., ⁇ O:342-349).
- cells were grown to near-confluency in DMEM supplemented with 10% FBS.
- Cell lysates were prepared, clarified, and assayed for protein concentration. Normalized aliquots of cell lysates were subjected to SDS-polyacrylamide gel electrophoresis, electrotransfer, and sequential immunodecoration with C-28 anti-Met polyclonal antibody and with anti- ⁇ -tubulin polyclonal antibody.
- Immune complexes were identified by enhanced chemiluminescence and visualized by exposure to X-ray film. Preparation and characterization of Met3 mAbs against the extracellular domain of human Met were produced and screened for reactivity as described above. Antibodies from the hybridoma clone 2F6 were identified as exhibiting the highest affinity for Met by ELISA and the highest apparent affinity for the human Met extracellular domain by IF. The antibodies from clone 2F6, used for the experiments described here, are designated Met3.
- Fluorescence-activated cell sorting (FACS) analysis of Met3 binding to cultured human prostate carcinoma cell lines was performed with a Becton Dickinson FACS Calibur instrument. Cultured cells were grown to near-confluency, detached and dissociated by chelation, and resuspended at about 10 6 cells/0.1 ml in BSA-containing buffer. The cell suspensions were incubated with Met3 (10 ⁇ g/ml) for 30 minutes at 4 C, washed thrice, incubated with secondary antibody (anti-mouse Alexa green, Molecular Probes) for 15 minutes at 4 C and washed thrice before analysis.
- Met3 (10 ⁇ g/ml) for 30 minutes at 4 C
- secondary antibody anti-mouse Alexa green, Molecular Probes
- IgG fractions were purified from 2F6 (Met3) hybridoma cell line supernatant fractions by protein G affinity chromatography and adjusted to a final concentration of 2 mg/ml in 0.25 sodium phosphate buffer, pH 6.8-7.0.
- the purified IgG fractions were stored frozen in small aliquots (25-50 ⁇ g) and thawed just prior to radioiodination.
- Met3 was radioiodinated by the procedure described above.
- the recovered product was stored at 4°C until used, and injected within 24 hours of labeling. Radiolabeling efficiency was
- mice Sedated mice were placed singly or in pairs on top of an inverted camera head with a protective layer over the collimator, and taped to the layer to maintain optimum limb extension. Images of 125 I activity were acquired on a Siemens LEM Plus mobile camera with a low-energy, high-sensitivity collimator. Acquisitions were obtained over a period of 15 minutes, during which we collected between 2xl0 5 and 3xl0 6 counts per total body image.
- Relative activity was determined by computer-assisted region-of-interest (ROI) analysis for each tumor, for total body, and for appropriate background regions at each imaging time point. These data are expressed below as background- and decay-conected activity ratios. Graphical and statistical analysis of the converted data utilized the program Excel (Microsoft).
- Met3 colocalizes with the commercially available polyclonal anti-Met antibody C-28 in cultured S-l 14 cells, a murine cell line transformed with human Met and human HGF/SF.
- Figure 5 A shows that Met3 may also be used for immunohistochemistry of human tissues, e.g., prostate tissue, in formalin-fixed, paraffin-embedded tissue sections.
- Figure 5B shows that the pattern of staining for Met3 by IF analysis in primary cultures of human prostate epithelial cells replicates that observed with C-28.
- Met3 binds to the surfaces of PC-3 and DU145 human prostate carcinoma cell lines, both of which express Met, but not to any significant level to the surface of LNCaP cells that express very little Met (Knudsen et al, supra). See Fig. 5C. Analysis of Met expression by cell lines
- the cell lines selected for this study vary dramatically in their relative expression of Met when cultured in the presence of serum.
- Cell lysates normalized to the concentration of cell protein were subjected to electrophoresis, electrotransfer, and immunodecoration with C-28 to assess the abundance of Met, and with anti- ⁇ -tubulin (as a control to verify comparable levels among the various cell lines of an irrelevant housekeeping gene product).
- S-l 14 showed the highest abundance of Met, both as pl70 precursor and mature pl40 forms.
- the melanoma cell lines expressed very low levels of Met, with M14-Mel lower than SK-MEL-28.
- SK-LMS-1/HGF and PC-3 cells exhibited intennediate abundance of Met, with comparable levels of total Met (pi 70 plus pi 40), but with a lower ratio of pl70 to pl40 detected in PC-3 cells.
- Figure 7 shows serial total body gamma camera images of individual xenograft-bearing
- mice 191 mice obtained between one to two hours and five to six days following i.v. injection of I- Met3.
- a pair of simultaneously imaged host mice is depicted for SK-LMS-1/HGF xenografts.
- Figure 8 shows graphical results of quantitative image ROI analysis, expressed in two forms.
- the upper panel displays the estimated fraction of injected activity associated with xenografts of differing tissue origin as a function of time postinjection. Each xenograft type exhibited the highest mean value for this function at the earliest imaging session, with respective maxima ( ⁇ 1 s.d.) of 18.6 ⁇ 2.1, 7.2+2.2, and 5.4+2.6 % of the estimated injected activity for S- 114, SK-LMS-1/HGF, and PC-3.
- the lower panel displays the mean ratios of tumor-to-total body activity as a function of time postinjection.
- Example 4 demonstrates that Met3, the product of a single hybridoma clone that recognizes a single epitope of the ECD hMet, is similarly effective for nuclear imaging.
- Met3 is useful for routine immunohistochemical analysis of formalin-fixed, paraffin-embedded sections of human tissue, for IF analysis of primary human cell cultures, and for FACS-based analyses of human tumor cells, in particular for the evaluation of samples of normal and malignant human prostate tissues. The results presented here, along with additional examples, confirm that radiolabeled
- Met3 images Met-expressing human tumor xenografts of differing tissue origins. Moreover, the rank order of 125 I-Met3 uptake and retention levels exhibited by different types of xenografts in vivo conelates directly with the rank order of relative Met abundance as assessed biochemically in the respective parent cell lines cultured in the presence of serum. Stated another way, based on these findings, it is possible to divide, arbitrarily, tumors into categories of high, low and intermediate Met3 uptake by nuclear imaging analysis and to infer that those respective categories reflect high, low, and intermediate abundance of Met in the tumor cells.
- a second anti-Met monoclonal antibody product from a single hybridoma clone, designated Met5 (see Table 1) was produced and screened essentially as described above for Met3. Immunoprecipitation and immunoblottmg analysis and FACS analysis indicates that the Met5 mAb binds both canine Met and human Met. Results now shown indicate that Met5 binds to a different epitope of the ECD of Met than does the Met3 mAb. The results are shown in Figures 9-13.
- Met was found to be present on canine cells.
- Cells of the canine kidney cell line MDCK were cultured and exposed to HGF at the indicated concentrations.
- Cell lysates were prepared and immunoprecipitated with Met5 followed by electrophoresis, electrotransfer, and immunodecoration with anti-PY 4G10 (anti-phosphotyrosine antibody)to detect activated
- radioiodinated Met5 is effective for imaging human tumor xenografts in nude mice.
- This reagent will permit Met-directed imaging and development of diagnostic and therapeutic agents for both humans as well as in pet dogs in which spontaneously occurring cancers of the prostate and bone are relatively common.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002472383A CA2472383A1 (en) | 2001-12-27 | 2002-12-27 | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
JP2003557514A JP2005527488A (en) | 2001-12-27 | 2002-12-27 | Monoclonal antibody imaging and treatment of tumors expressing Met and binding to hepatocyte growth factor |
AU2002357388A AU2002357388A1 (en) | 2001-12-27 | 2002-12-27 | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
US10/500,297 US20050118165A1 (en) | 2001-12-27 | 2002-12-27 | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
EP02806253A EP1516185A4 (en) | 2001-12-27 | 2002-12-27 | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34239801P | 2001-12-27 | 2001-12-27 | |
US60/342,398 | 2001-12-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003057155A2 true WO2003057155A2 (en) | 2003-07-17 |
WO2003057155A3 WO2003057155A3 (en) | 2005-01-20 |
Family
ID=23341661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/041607 WO2003057155A2 (en) | 2001-12-27 | 2002-12-27 | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050118165A1 (en) |
EP (1) | EP1516185A4 (en) |
JP (1) | JP2005527488A (en) |
AU (1) | AU2002357388A1 (en) |
CA (1) | CA2472383A1 (en) |
WO (1) | WO2003057155A2 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072117A2 (en) * | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
WO2006132251A1 (en) * | 2005-06-08 | 2006-12-14 | Kringle Pharma Inc. | Prophylactic/therapeutic agent for adult t cell leukemia |
EP1774317A1 (en) * | 2004-07-13 | 2007-04-18 | Van Andel Research Institute | IMMUNE-COMPROMISED TRANSGENIC MICE EXPRESSING HUMAN HEPATOCYTE GROWTH FACTOR (hHGF) |
EP1952826A1 (en) * | 2005-10-24 | 2008-08-06 | Fujifilm RI Pharma Co., Ltd. | Diagnostic agent and therapeutic agent for disease associated with hepatocyte growth factor receptor |
US7494650B2 (en) | 2003-04-18 | 2009-02-24 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
EP2127683A1 (en) | 2008-05-29 | 2009-12-02 | Metheresis Translational Research SA | Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits |
US7632926B2 (en) | 2006-04-01 | 2009-12-15 | Galaxy Biotech, Llc | Humanized monoclonal antibodies to hepatocyte growth factor |
WO2012022676A1 (en) | 2010-08-18 | 2012-02-23 | Ge Healthcare Limited | Peptide radiotracer compositions |
WO2012119937A1 (en) | 2011-03-04 | 2012-09-13 | Ge Healthcare Limited | Technetium labelled peptides |
WO2013045662A1 (en) | 2011-09-28 | 2013-04-04 | Ge Healthcare As | Peptide margin imaging agents |
WO2013045650A2 (en) | 2011-09-30 | 2013-04-04 | Ge Healthcare As | Infusion imaging method |
WO2013092742A1 (en) | 2011-12-20 | 2013-06-27 | Ge Healthcare Limited | Method for patient selection |
US8609090B2 (en) | 2003-07-18 | 2013-12-17 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
US9068011B2 (en) | 2010-03-10 | 2015-06-30 | Genmab A+S | Monoclonal antibodies against c-Met |
US9169329B2 (en) | 2010-06-01 | 2015-10-27 | Ludwig Institute For Cancer Research | Antibodies directed to the receptor tyrosine kinase c-Met |
US9201074B2 (en) | 2011-09-20 | 2015-12-01 | Eli Lilly And Company | Anti-c-Met antibodies |
US10300156B2 (en) | 2013-12-18 | 2019-05-28 | Ge Healthcare Limited | Radiotracer compositions and methods |
US10548995B2 (en) | 2013-08-21 | 2020-02-04 | Ge Healthcare Limited | Radiolabelling method |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9757476B2 (en) * | 2006-06-08 | 2017-09-12 | Warsaw Orthopedic, Inc. | Compositions and methods for diagnosis of axial pain with or without radiculopathy |
US20090099660A1 (en) * | 2007-10-10 | 2009-04-16 | Warsaw Orthopedic, Inc. | Instrumentation to Facilitate Access into the Intervertebral Disc Space and Introduction of Materials Therein |
US20090297439A1 (en) * | 2008-06-02 | 2009-12-03 | Metheresis Translational Research Sa, | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits |
US20140301952A1 (en) * | 2009-04-30 | 2014-10-09 | Pharmacophotonics, Inc. D/B/A Fast Diagnostics | Measurement of body fluid volumes |
US20120276014A1 (en) * | 2009-04-30 | 2012-11-01 | Pharmacophotonics, Inc. | Measurement of body fluid volumes |
EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
CN104974258B (en) * | 2014-04-01 | 2019-06-14 | 三生国健药业(上海)股份有限公司 | Recombinate anti-HGF/DLL4 bispecific antibody, preparation method and application |
WO2016149265A1 (en) | 2015-03-16 | 2016-09-22 | Kolltan Pharmaceuticals, Inc. | Anti-met antibodies and methods of use thereof |
US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU729029B2 (en) * | 1996-07-03 | 2001-01-25 | Genentech Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
AU1598801A (en) * | 1999-11-09 | 2001-06-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | HGF-SF monoclonal antibody combinations |
-
2002
- 2002-12-27 EP EP02806253A patent/EP1516185A4/en not_active Withdrawn
- 2002-12-27 US US10/500,297 patent/US20050118165A1/en not_active Abandoned
- 2002-12-27 WO PCT/US2002/041607 patent/WO2003057155A2/en active Application Filing
- 2002-12-27 AU AU2002357388A patent/AU2002357388A1/en not_active Abandoned
- 2002-12-27 JP JP2003557514A patent/JP2005527488A/en active Pending
- 2002-12-27 CA CA002472383A patent/CA2472383A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
PRAT ET AL.: 'C-terminal truncated forms of Met, the hepatocyte growth factor receptor' MOL. CELL. BIOL. vol. 11, no. 12, December 1991, pages 5954 - 5962, XP002903959 * |
See also references of EP1516185A2 * |
YAMADA ET AL.: 'Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (cMet) in human brain tissues' BRAIN RES. vol. 637, 1994, pages 308 - 312, XP000863216 * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072117A3 (en) * | 2003-02-13 | 2005-01-06 | Pharmacia Corp | Antibodies to c-met for the treatment of cancers |
WO2004072117A2 (en) * | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
US7494650B2 (en) | 2003-04-18 | 2009-02-24 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
US7687063B2 (en) | 2003-04-18 | 2010-03-30 | Galaxy Biotech, Llc | Treating solid tumors with an antibody to hepatocyte growth factor |
US8609090B2 (en) | 2003-07-18 | 2013-12-17 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
EP1774317A4 (en) * | 2004-07-13 | 2010-11-03 | Van Andel Res Inst | IMMUNE-COMPROMISED TRANSGENIC MICE EXPRESSING HUMAN HEPATOCYTE GROWTH FACTOR (hHGF) |
EP1774317A1 (en) * | 2004-07-13 | 2007-04-18 | Van Andel Research Institute | IMMUNE-COMPROMISED TRANSGENIC MICE EXPRESSING HUMAN HEPATOCYTE GROWTH FACTOR (hHGF) |
US7968762B2 (en) | 2004-07-13 | 2011-06-28 | Van Andel Research Institute | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) |
WO2006132251A1 (en) * | 2005-06-08 | 2006-12-14 | Kringle Pharma Inc. | Prophylactic/therapeutic agent for adult t cell leukemia |
EP1952826A4 (en) * | 2005-10-24 | 2011-05-18 | Fujifilm Ri Pharma Co Ltd | Diagnostic agent and therapeutic agent for disease associated with hepatocyte growth factor receptor |
EP1952826A1 (en) * | 2005-10-24 | 2008-08-06 | Fujifilm RI Pharma Co., Ltd. | Diagnostic agent and therapeutic agent for disease associated with hepatocyte growth factor receptor |
US7632926B2 (en) | 2006-04-01 | 2009-12-15 | Galaxy Biotech, Llc | Humanized monoclonal antibodies to hepatocyte growth factor |
US8628778B2 (en) | 2006-04-01 | 2014-01-14 | Galaxy Biotech, Llc | Humanized monoclonal antibodies to hepatocyte growth factor |
EP2127683A1 (en) | 2008-05-29 | 2009-12-02 | Metheresis Translational Research SA | Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits |
US11512140B2 (en) | 2010-03-10 | 2022-11-29 | Genmab A/S | Monoclonal antibodies against c-Met |
US9657107B2 (en) | 2010-03-10 | 2017-05-23 | Genmab A/S | Monoclonal antibodies against c-Met |
US9068011B2 (en) | 2010-03-10 | 2015-06-30 | Genmab A+S | Monoclonal antibodies against c-Met |
US9169329B2 (en) | 2010-06-01 | 2015-10-27 | Ludwig Institute For Cancer Research | Antibodies directed to the receptor tyrosine kinase c-Met |
WO2012022676A1 (en) | 2010-08-18 | 2012-02-23 | Ge Healthcare Limited | Peptide radiotracer compositions |
WO2012119937A1 (en) | 2011-03-04 | 2012-09-13 | Ge Healthcare Limited | Technetium labelled peptides |
US9259496B2 (en) | 2011-03-04 | 2016-02-16 | Ge Healthcare Limited | Technetium labelled peptides |
US9201074B2 (en) | 2011-09-20 | 2015-12-01 | Eli Lilly And Company | Anti-c-Met antibodies |
WO2013045662A1 (en) | 2011-09-28 | 2013-04-04 | Ge Healthcare As | Peptide margin imaging agents |
WO2013045650A2 (en) | 2011-09-30 | 2013-04-04 | Ge Healthcare As | Infusion imaging method |
WO2013092742A1 (en) | 2011-12-20 | 2013-06-27 | Ge Healthcare Limited | Method for patient selection |
US10548995B2 (en) | 2013-08-21 | 2020-02-04 | Ge Healthcare Limited | Radiolabelling method |
US10300156B2 (en) | 2013-12-18 | 2019-05-28 | Ge Healthcare Limited | Radiotracer compositions and methods |
US11311636B2 (en) | 2013-12-18 | 2022-04-26 | Ge Healthcare Limited | Radiotracer compositions and methods |
Also Published As
Publication number | Publication date |
---|---|
EP1516185A2 (en) | 2005-03-23 |
WO2003057155A3 (en) | 2005-01-20 |
US20050118165A1 (en) | 2005-06-02 |
EP1516185A4 (en) | 2007-06-20 |
CA2472383A1 (en) | 2003-07-17 |
JP2005527488A (en) | 2005-09-15 |
AU2002357388A1 (en) | 2003-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050118165A1 (en) | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor | |
CN1675245B (en) | Monoclonal antibody hPAM4 | |
US8101713B2 (en) | Prostate cancer diagnosis and treatment | |
KR101468397B1 (en) | Methods for treating breast cancer | |
KR102232811B1 (en) | Therapeutic agents and uses thereof | |
CN101022830A (en) | Ligands binding the complex of urokinase-type plasminogen activator(uPA) and its receptor(uPAR) that inhibit downstream upar interactions: identification and use in diagnosis or therapy | |
US20040265930A1 (en) | Monoclonal antibody 7H11 reactive with human cancer | |
US20030082188A1 (en) | Treatment of prostate cancer by inhibitors of NCAM2 | |
IL127193A (en) | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments and use thereof for the prophylaxis and detection of cancers | |
US10239954B2 (en) | Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer | |
AU2006235421A1 (en) | Conjugated anti-PSMA antibodies | |
US20200262929A1 (en) | Anti-cd146 antibodies and uses thereof | |
AU2003251966A1 (en) | Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells | |
CN118159558A (en) | Anti-DLL 3 antibodies and uses thereof | |
US20070025911A1 (en) | Cancer specific monoclonal antibodies | |
KR101875912B1 (en) | Radiolabeled anti-CD55 antibody for the diagnosis and therapy of cancer and use thereof | |
US20050260132A1 (en) | Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta | |
US11396538B2 (en) | Antibodies to centrin-1, methods of making, and uses thereof | |
CA2546237A1 (en) | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof | |
CN114729034A (en) | Affinity matured anti-ASIC 1a antibodies | |
CA2255540C (en) | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002357388 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2472383 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003557514 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10500297 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002806253 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002806253 Country of ref document: EP |